Conclusions: Ranibizumab combined with laser photocoagulation in the treatment of macular edema secondary to ischemic retinal vein occlusion presents significant efficacy, and can effectively reduce macular volume, improve visual acuity and promote the recovery of retinal function.

Conclusions: The Bio-USER survey revealed that while the majority of retinal physicians need additional information regarding the safety, efficacy and immunogenicity when making clinical decisions regarding their use. Retinal physicians from US are more comfortable in continuing to use off-label bevacizumab compared to physicians from...

Key Messages: Anti‐VEGFs (combined with or without laser) improve the vision, but the degree of improvement is not clinically meaningful. They also reduce the formation of new vessels, haemorrhages, and the need for removing the vitreous with surgery (vitrectomy). The safety of anti‐VEGFs (combined with or without laser) remains uncertain...

Conclusion: Long-term efficacy of aflibercept and ranibizumab was largely consistent. Following a two-year intensive therapy with as-needed regimen, BCVA was maintained or improved in almost half of the patients and in the ranibizumab group and more than half of the patients in the aflibercept group with very few injections. In a remarkable...

Conclusion: There is no significant difference in treatment efficacies in both visual and anatomical outcomes at the end of the 6th month. However, RAN can be considered the first choice in younger patients with macular edema secondary to branch RVO because of the lower side effect profile.